Omapatrilat Synthesis for High Optical Purity and Low Impurities
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing Compound 1, a dual neprilysin and angiotensin converting enzyme inhibitor, face challenges in achieving high yields and optical purity, leading to impurities that affect its efficacy in treating conditions like hypertension.
Innovation Solution
A refined production process involving specific reaction steps and purifications, including disulfide bond cleavage, acid-catalyzed cyclization, and controlled coupling reactions, results in a Compound 1 with greater than 97% purity and less than 3% total impurities, ensuring high optical purity and reduced iso-Compound 1 content.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If existing production methods are used for Compound 1, then the production process is simpler, but the yield and optical purity are insufficient leading to high impurity content
Solution Approach 1:
The patent applies preliminary action by performing disulfide bond cleavage and acid-catalyzed cyclization as preparatory steps before the main coupling reaction. These preliminary steps pre-organize the molecular structures and activate the reactants, ensuring that when the coupling reaction occurs, it proceeds with high stereoselectivity to produce Compound 1 with greater than 98% optical purity. The preliminary actions set up the reaction conditions to favor the desired enantiomer formation from the outset.
Solution Approach 2:
The patent employs parameter changes by carefully controlling reaction conditions including temperature, pH, solvent composition, and catalyst concentration throughout the synthesis process. Specific parameters such as the acid catalyst concentration during cyclization and the coupling reagent stoichiometry are optimized to maximize optical purity. These parameter adjustments transform the reaction pathway to favor high enantiomeric excess while maintaining reasonable process complexity.
2Manufacturing precision
If existing production methods are used for Compound 1, then the process steps are fewer, but the total impurity content exceeds acceptable levels
Solution Approach 1:
The patent applies the extraction principle by systematically removing impurities at multiple stages of the synthesis process. Chromatographic purification steps are inserted after key reactions to extract and separate Compound 1 from byproducts and unwanted isomers. This multi-stage extraction approach ensures that the final product contains less than 3% total impurities, meeting pharmaceutical quality standards while maintaining production efficiency through optimized purification protocols.
Solution Approach 2:
The patent converts the potential harm of intermediate impurities into benefit by using them as diagnostic tools. Specific impurity profiles generated during synthesis serve as indicators of reaction progress and quality. By monitoring these impurities through analytical methods, the process can be adjusted in real-time to prevent excessive impurity formation, thereby maintaining high purity without requiring excessive additional purification steps that would reduce productivity.
3Productivity
If existing production methods are used for Compound 1, then the synthesis is faster, but the yield is reduced
Solution Approach 1:
The patent implements continuity of useful action by designing a synthesis pathway where each reaction step flows directly into the next without unnecessary interruptions. The disulfide bond cleavage, acid-catalyzed cyclization, and coupling reactions are sequenced to maintain continuous transformation of reactants toward the final product. This continuous action minimizes idle time and maximizes overall yield, achieving greater than 97% purity with acceptable synthesis time by eliminating non-productive pauses in the reaction sequence.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The improved process enhances the yield and optical purity of Compound 1, thereby improving its effectiveness in treating hypertension and other conditions by minimizing impurities and ensuring consistent pharmaceutical quality.
Implementation Method 1
reacting Compound 4 or a salt thereof with a reagent that cleaves the disulfide bond to produce a thiol monomer
Implementation Method 2
subjecting the monomer from step (i)(a) to an acid catalyzed cyclization reaction in a suitable solvent to provide Compound 5
Implementation Method 3
reacting Compound 6 with Compound 7 or a salt thereof in the presence of a coupling reagent to provide Compound 8
Data Source
AI summary
Described herein are improved methods of making Compound 1 (4S,7S,10aS)-4-((S)-2-mercapto-3-phenylpropanamido)-5-oxooctahydro-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid, or Omapatrilat, and purified Omapatrilat obtained from the improved methods.